Biogen, Eisai stocks fall despite receiving FDA approval for Alzheimer's drug

Shares of pharmaceutical developers Biogen and Eisai are falling in the after-hours session. This comes following the companies received official FDA approval for their Alzheimer's treatment drug, Leqembi. Yahoo Finance Healthcare Reporter Anjalee Khemlani joins the Live show to detail the treatment plan.